BindingDB Data by Journal
PMID
Data
Article Title
Citation
Organization
Download Data
Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WIPO 0: 0-0 (2005)
Pfizer
Compounds and methods for the treatment of covid-19
WIPO 0: 0-0 (2021)
Pfizer
Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infections
WIPO 0: 0-0 (2021)
Insilico Medicine Ip
CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS
WIPO 0: 0-0 (2022)
Janssen Pharmaceutica
Aminocarbamoyl compounds for the treatment of viral infections
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS
WIPO 0: 0-0 (2022)
Bristol-Myers Squibb
DIHYDROOROTATE DEHYDROGENASE INHIBITORS
WIPO 0: 0-0 (2022)
Janssen Biotech
PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
NOVEL CORONAVIRUS MAIN PROTEASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WIPO 0: 0-0 (2022)
Sichuan University
DIHYDROOROTATE DEHYDROGENASE INHIBITORS
WIPO 0: 0-0 (2022)
Janssen Biotech
DIHYDROOROTATE DEHYDROGENASE INHIBITORS
WIPO 0: 0-0 (2022)
Janssen Biotech
PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS
WIPO 0: 0-0 (2022)
Novartis
SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER
WIPO 0: 0-0 (2022)
The Broad Institute
SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER
WIPO 0: 0-0 (2022)
The Broad Institute
PHOSPHOLIPID COMPOUNDS AND USES THEREOF
WIPO 0: 0-0 (2022)
Gilead Sciences
7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER
WIPO 0: 0-0 (2022)
Genentech
1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXYPYRROLIDINE-2-CARBOXA|MIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA
WIPO 0: 0-0 (2022)
Genentech
SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE
WIPO 0: 0-0 (2022)
Janssen Pharmaceutica
CYCLOPENTATHIOPHENE CARBOXAMIDE DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS
WIPO 0: 0-0 (2022)
Boehringer Ingelheim International
HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
WIPO 0: 0-0 (2022)
Amgen
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES
WIPO 0: 0-0 (2022)
Novartis
INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7)
WIPO 0: 0-0 (2023)
Dana-Farber Cancer Institute
CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAME
WIPO 0: 0-0 (2023)
Baylor College of Medicine
CDK7 SELECTIVE INHIBITORS AS ANTICANCER AGENTS
WIPO 0: 0-0 (2023)
Jingrui Biopharma
NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOF
WIPO 0: 0-0 (2023)
Novo Nordisk
M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES
WIPO 0: 0-0 (2023)
Lycia Therapeutics
POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS
WIPO 0: 0-0 (2022)
Gilead Sciences
TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND INFLAMMATORY DISEASES
WIPO 0: 0-0 (2022)
Sanofi
MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
WIPO 0: 0-0 (2022)
Vertex Pharmaceuticals
INHIBITION OF TYK2 DEPENDENT SIGNALING PATHWAYS
WIPO 0: 0-0 (2022)
Janssen Pharmaceutica
ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
AROMATIC BRIDGED RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS
WIPO 0: 0-0 (2022)
Boehringer Ingelheim International
7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORS
WIPO 0: 0-0 (2022)
Eli Lilly
N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER
WIPO 0: 0-0 (2022)
Bayer Aktiengesellschaft
SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WIPO 0: 0-0 (2022)
Sanofi
N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
WIPO 0: 0-0 (2022)
F. Hoffmann-La Roche
(AZA)BENZOTHIAZOLYL SUBSTITUTED PYRAZOLE COMPOUNDS
WIPO 0: 0-0 (2022)
Pfizer
3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS
WIPO 0: 0-0 (2022)
Merck Sharp &Amp
SARS-COV-2 MPRO INHIBITOR COMPOUNDS
WIPO 0: 0-0 (2022)
Heptares Therapeutics
SEROTONIN 5-HT2A, 5-HT2B, AND 5-HT2C RECEPTOR INVERSE AGONISTS
WIPO 0: 0-0 (2023)
Northeastern University
INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
WIPO 0: 0-0 (2023)
Mindset Pharma
Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WIPO 0: 0-0 (2006)
Pfizer